Nanogen Considering Selling or Closing Array Business to Achieve Profitability
 
Nanogen said this week that it is “evaluating strategic alternatives for its microarray business as part of an aggressive plan to achieve profitability.” The San Diego firm’s array business includes its NanoChip 400 instrument system and related multiplexed reagents and consumables. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.